Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07482657
PHASE2

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Sponsor: Enanta Pharmaceuticals, Inc

View on ClinicalTrials.gov

Summary

Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.

Official title: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Key Details

Gender

All

Age Range

28 Days - 36 Months

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-07

Completion Date

2026-12

Last Updated

2026-03-19

Healthy Volunteers

No

Interventions

DRUG

zelicapavir

Oral suspension

DRUG

Placebo

Placebo oral suspension to match zelicapavir